| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 2.2K | -86% |
| Gross Profit | -137K | - |
| Cost Of Revenue | 139.2K | - |
| Operating Income | -2MM | -9% |
| Operating Expenses | 1.8MM | -15% |
| Net Income | -3.1MM | -6% |
| R&D | 72.2K | -49% |
| G&A | 1.5MM | +29% |
| Interest Expense | 1.1MM | -9% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
FREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, an...
FREMONT, CA - (NewMediaWire) - April 17, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, ann...
FREMONT, CA - (NewMediaWire) - April 10, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, ann...
FREMONT, CA - (NewMediaWire) - March 26, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, ann...
ABVC's subsidiary AIBL entered into Agreement to exchange 100% ownership stake in certain real estate for 1,533,333 AIBL shares at $5/share
FREMONT, CA - (NewMediaWire) - March 19, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that ...
FREMONT CA - (NewMediaWire) - March 14, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its ...
FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today provided an update on its development of combination therapy for the treatment of cancer and immunity booster dietary supplements. The Company is currently marketing dietary supplements, as well as continuing to pursue clinical t
FREMONT, CA - (NewMediaWire) - February 15, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that...
The Company holds a U.S. patent for the same treatmentFREMONT, CA - (NewMediaWire) - February 12, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, ne...